Unicycive Therapeutics, Inc.披露，美国食品药品监督管理局（FDA）已正式接受其针对碳酸氧镧（OLC）的新药申请（NDA）重新提交。该进展标志着公司在推进该药物治疗方案方面迈出重要一步。
Unicycive Therapeutics, Inc.披露，美国食品药品监督管理局（FDA）已正式接受其针对碳酸氧镧（OLC）的新药申请（NDA）重新提交。该进展标志着公司在推进该药物治疗方案方面迈出重要一步。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.